ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ENTA vs TTRX // RSI-14 & 200D SMA MOMENTUM

Enanta Pharmaceuticals Inc. (NASDAQ) VS. Turn Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ENTA 1 — TTRX 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: TTRX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENTA VS. TTRX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ENTA TTRX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -28.30% -6.70 TTRX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.91% -0.78% -9.13 TTRX /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -3.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 1/9 +2.00 ENTA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 36.6 43.4 -6.72 TTRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $324.7M $327.3M -$2.6M TTRX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ENTA REV TTRX REV ENTA GROSS % TTRX GROSS % ENTA FCF TTRX FCF
FY 2025 $65.3M $0 — — -$32.2M -$2.6M
FY 2024 $67.6M $0 — — -$96.7M -$1.4M
FY 2023 $79.2M — — — -$103.2M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENTA // BETA —
TTRX // BETA —